# A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)

> **NCT04948554** · PHASE1 · TERMINATED · sponsor: **Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA** · enrollment: 5 (actual)

## Conditions studied

- Systemic Sclerosis With and Without Interstitial Lung Disease

## Interventions

- **BIOLOGICAL:** MK-2225
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT04948554
- **Lead sponsor:** Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-03-10
- **Primary completion:** 2023-10-18
- **Final completion:** 2023-10-18
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Business Reasons
- **Last updated:** 2023-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04948554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04948554, "A Study of MK-2225 / ACE-1334 in Participants With Systemic Sclerosis With and Without Interstitial Lung Disease (MK-2225-002)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04948554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*